LIVE SESSION BRIEF Pharmaceuticals & Therapeutics $3.72B Cap Quant: BUY

Akero Therapeutics, Inc. (AKRO) — Live Session & Technical Brief

Updated Nov 21, 2026 5:01 AM ET · Prev Close $54.48

Pro Workspace
Last Session Price
$54.65 +0.32%
+$0.17 vs $54.48 prior close
Intraday Range
$54.37 – $54.83
Open $54.52
Relative Volume
11.60x Avg
15,409,003 sh
52-Week Range
$21.34 – $58.40
Benchmark Alpha
+3.96% vs SPY
+5.99% vs QQQ
20-Session Trend +0.9%

Session Regime & Catalyst Assessment

64% Signal Conviction
TECHNICAL 64% Driver Weight

Controlled Session Consolidation (+0.32%) in Pharmaceuticals & Therapeutics

Akero Therapeutics, Inc. (AKRO) is trading within a tight intraday band at $54.65 (+0.32%, 11.60x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, AKRO is outperforming the S&P 500 by +3.96%. 14-day RSI stands at 67.3, keeping momentum in a bullish regime.

NEWS 70% Weight
Novo Nordisk has completed its acquisition of Akero Therapeutics

Bagsværd, Denmark and South San Francisco, Ca, Us, 9 December 2025 Novo Nordisk and Akero Therapeutics Inc. Akero Nasdaq AKRO today announced that Novo Nordisk s acquisition of Akero, announced on 9 October 2025, has bee

TECHNICAL 68% Weight
Moving Average Structure: Bullish Alignment

Price ($54.65) holds above both 20-day ($54.36) and 50-day ($52.91) moving averages.

Volume Confirmation
HIGH VOLUME (11.60x) Accumulation
Institutional participation confirms directional price action.
Composite Catalyst Confidence 64%
Cross-checked across volume tape, benchmark alpha, options flow, and news.

Market & Sector Relative Strength

AKRO outperforming the S&P 500 by +3.96%
AKRO Session
+0.32%
$54.65
S&P 500 (SPY)
-3.64%
$689.81
Nasdaq 100 (QQQ)
-5.67%
$608.45
Healthcare (XLV)
-0.12%
$177.24
Alpha vs SPY: +3.96% Alpha vs QQQ: +5.99% Alpha vs XLV: +0.44%

Recent AKRO Catalyst Headlines

Verified Wire

1–3 Day Expected Range & Key Level

54% Follow-Through
Lower Bound
$53.43
Short-term support band
Upper Bound
$55.87
Short-term resistance band
Key Inflection Level
$54.36 (20-day SMA support)

Monitor volume expansion above 1.5x RVOL around $54.36 (20-day SMA support) for directional breakout confirmation.

Technical Regime (AKRO)

BULLISH MA TREND
RSI (14)
67.3
Bullish
20-Day SMA
$54.36
Above 20d
50-Day SMA
$52.91
Above 50d
MACD Signal
Bearish
MACD 0.45
ADX (14)
34.5
Strong trend
10d Momentum
+0.19
Positive 10-day momentum

Retail & Crowd Sentiment

Neutral
24h Messages
0
7d avg 0.0
Bullish / Bearish
0.0% / 0.0%
None buzz
Crowd Discussion Digest

Traders on StockTwits express bullish sentiment towards SAIH, anticipating a potential multi-day price surge as momentum picks up.

Reddit communities: 2 comments (Neutral)

About Akero Therapeutics, Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address …

Sector
Pharmaceuticals & Therapeutics
Market Cap
$3.72B
Employees
67

Get Instant AKRO Catalyst Alerts

Receive an email alert when AKRO triggers an unusual volume breakout, options sweep, or rating shift.

Other Liquid Stocks Moving Today

All Today's Movers

AKRO Session & Catalyst FAQ

Why is AKRO stock trading near flat today?

Akero Therapeutics, Inc. (AKRO) is trading within a tight intraday band at $54.65 (+0.32%, 11.60x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, AKRO is outperforming the S&P 500 by +3.96%. 14-day RSI stands at 67.3, keeping momentum in a bullish regime.

Is AKRO stock a buy or sell right now?

Today's session carries a 64% catalyst conviction score on 11.60x relative volume (high participation). Our multi-factor model currently rates AKRO as BUY. Review full valuation, quality, and timing signals on the AKRO Buy or Sell Decision Brief →

What is AKRO's intrinsic value and expected trading range?

At $54.65, AKRO's modeled 1-to-3 session range is $53.43 – $55.87, with a key inflection level at $54.36 (20-day SMA support). Compare current price against multi-year cash flow projections in the AKRO Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →

What do RSI and moving averages signal for AKRO?

RSI at 67.3 reflects constructive bullish momentum. AKRO trades at $54.65 relative to its 20-day SMA ($54.36) and 50-day SMA ($52.91), reflecting a bullish moving-average structure.

Tradestie Flagship Research & Market Hubs